Clinical Trials Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Aug 7, 2017; 23(29): 5395-5404
Published online Aug 7, 2017. doi: 10.3748/wjg.v23.i29.5395
Table 1 Characteristics of all the patients
PatientsAgeSexBCLC stageHKTumor site(s)Radiotherapy targetDose of radiotherapyCycle(s) of PPV-DC-CTL
P166MaleBIIIBLiverPartial liver massPGTV 5 Gy*10f; PTV 2.5 Gy*10f3
P256FemaleBIIIBLiverPartial liver massPGTV 5 Gy*10f; PTV 2.5 Gy*10f3
P354MaleCIVaLiver and portal vein tumor thrombosisPortal vein tumor thrombosisPGTV 5 Gy*10f; PTV 2.5 Gy*10f2
P437MaleCIVaBone and lungBone metastasisPGTV 4 Gy*10f; PTV 3 Gy*10f3
P556MaleCIVaLiver and peritoneal metastasesPeritoneal metastasisPTV 0.5 Gy BID *2f2
P645MaleBIIIBLiver--2
P743MaleBIIIBLiverPartial liver massPGTV 5 Gy*10f; PTV 2.5 Gy*10f3
P859MaleCIVaLiver and lungPartial lung massPGTV 5 Gy*10f; PTV 2.5 Gy*10f1
P972MaleCIVaLung--2